Top Page
EKF Diagnostics Holdings
(LSE:EKF)
EKF Diagnostics Holdings (EKF) vs. iShares MSCI United Kingdom ETF (EWC)
EKF Diagnostics Holdings Business Overview & Revenue Model
EKF Diagnostics Holdings Earnings Call Summary
EKF Diagnostics Holdings Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 50.22M | 50.19M | 52.61M | 66.64M | 81.84M | 65.26M |
| Gross Profit | 25.00M | 21.48M | 23.86M | 24.04M | 39.37M | 37.42M |
| EBITDA | 11.47M | 11.16M | 7.68M | -2.18M | 27.39M | 20.04M |
| Net Income | 6.12M | 6.24M | 2.35M | -10.10M | 15.85M | 11.11M |
Balance Sheet | ||||||
| Total Assets | 82.43M | 81.75M | 80.85M | 89.29M | 115.12M | 101.27M |
| Cash, Cash Equivalents and Short-Term Investments | 16.62M | 13.01M | 6.02M | 11.58M | 20.34M | 21.91M |
| Total Debt | 1.12M | 1.32M | 4.10M | 1.55M | 3.47M | 1.96M |
| Total Liabilities | 9.55M | 8.53M | 12.63M | 14.77M | 20.38M | 23.07M |
| Stockholders Equity | 71.73M | 72.33M | 67.12M | 73.35M | 94.12M | 77.65M |
Cash Flow | ||||||
| Free Cash Flow | 9.47M | 11.41M | -664.00K | 3.86M | 4.59M | 11.16M |
| Operating Cash Flow | 10.71M | 13.66M | 6.31M | 9.69M | 10.24M | 13.81M |
| Investing Cash Flow | -1.84M | -2.66M | -5.64M | -8.93M | -5.48M | 1.34M |
| Financing Cash Flow | -1.44M | -4.08M | -3.65M | -11.04M | -6.16M | -5.21M |
EKF Diagnostics Holdings Technical Analysis
EKF Diagnostics Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £91.44M | 12.05 | 64.40% | 8.33% | -3.61% | -6.35% | |
67 Neutral | £109.57M | 18.74 | 8.71% | ― | -1.43% | 28.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £4.64M | 3.42 | 13.26% | ― | -10.20% | 714.29% | |
45 Neutral | £16.32M | -6.84 | -90.48% | ― | 37.39% | -126.19% | |
44 Neutral | £8.75M | -0.91 | -153.92% | ― | 90.42% | 79.21% | |
43 Neutral | £27.31M | -0.44 | 425.97% | ― | -4.48% | 61.09% |
EKF Diagnostics Holdings Corporate Events
EKF Diagnostics Holdings has repurchased 142,000 ordinary shares at a price of 26 pence per share, with the shares to be held in treasury, leaving 433,076,112 shares in issue carrying voting rights. As part of the buyback, the company acquired 42,000 shares from funds managed by Harwood, a move designed to keep non-executive director Christopher Mills’ aggregate indirect holding at about 127.7 million shares and ensure his interest remains around but below 30% of EKF’s total voting rights, clarifying the updated capital structure and major shareholder position for investors.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 200,000 of its ordinary shares at a weighted average price of 25.989p per share, placing the stock in treasury and leaving 433,218,112 shares in issue with voting rights out of a total issued share capital of 435,383,092. As part of this buyback, the company acquired 59,000 shares from funds managed by Harwood, ensuring that non-executive director Christopher Mills’ aggregate indirect stake remains at roughly 30% of voting rights, a move that fine-tunes the shareholder structure while supporting capital management objectives and maintaining regulatory thresholds for major shareholdings.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has bought back 267,000 of its ordinary shares at a price of 26 pence each, placing the repurchased stock into treasury and leaving 433,418,112 shares in issue with voting rights. As part of the transaction, the company acquired 79,000 shares from funds managed by Harwood in order to keep Non-Executive Director Christopher Mills’ aggregate indirect beneficial interest at roughly the same proportion of total voting rights and below the 30% threshold, a move that fine-tunes EKF’s capital structure and maintains regulatory comfort for major shareholders.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 142,000 of its own ordinary shares at a weighted average price of 26.4 pence, placing the shares into treasury and leaving 433,685,112 shares in issue with voting rights, a move that marginally adjusts the company’s capital structure and provides a new denominator for major shareholding disclosures. As part of this buyback, EKF also acquired 42,000 shares from funds managed by Harwood to ensure that non-executive director Christopher Mills’ aggregate indirect holding, now 127,886,000 shares, remains around but below 30% of the company’s voting rights, addressing regulatory thresholds and preserving the existing balance of shareholder control.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 142,000 of its ordinary shares at 26.1 pence each, with the shares to be held in treasury, leaving 433,827,112 shares in issue carrying voting rights. As part of the transaction, the company acquired 42,000 shares from funds managed by Harwood to keep non-executive director Christopher Mills’ aggregate indirect holding at around its previous level and below 30% of voting rights, a move that fine-tunes EKF’s capital structure and major shareholder positioning while providing clarity for investors on future disclosure thresholds.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 43,000 ordinary shares at a weighted average price of 25.56 pence, with the shares to be held in treasury, leaving 433,969,112 shares in issue carrying voting rights. As part of the transaction, the company bought 13,000 shares from funds managed by Harwood to ensure that non-executive director Christopher Mills’ aggregate indirect holding, now 127,970,000 shares, remains at around but not above 30% of EKF’s total voting rights, a move that fine-tunes the firm’s capital structure and major shareholder positioning for regulatory purposes.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 639,000 ordinary shares at a volume-weighted average price of 24.96p per share, with the shares to be held in treasury, leaving 434,012,112 shares carrying voting rights out of a total issued share capital of 435,383,092. As part of the buyback, the company acquired 189,000 shares from funds managed by Harwood Capital, a move designed to keep Non-Executive Director Christopher Mills’ aggregate indirect beneficial interest at roughly its previous level and below 30% of voting rights, thereby managing ownership concentration and maintaining compliance with UK disclosure and takeover thresholds.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has bought back 71,000 of its own ordinary shares at 25.5 pence each, all of which will be held in treasury, reducing the number of shares in circulation to 434,651,112 with voting rights. As part of the transaction, the company acquired 21,000 shares from funds managed by Harwood to ensure that non-executive director Christopher Mills’ aggregate indirect interest remains around, but does not exceed, 30% of EKF’s total voting rights, leaving him with an indirect holding of 128,172,000 shares, a move that consolidates the capital structure while managing a significant shareholder’s regulatory threshold.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 71,000 of its own ordinary shares at a weighted average price of 25.3 pence, with the shares to be held in treasury, leaving 434,722,112 shares in issue carrying voting rights. As part of the buyback, 21,000 shares were acquired from funds managed by Harwood to ensure that non-executive director Christopher Mills’ aggregate indirect holding, now 128,193,000 shares, remains at around 30% of the company’s voting rights, a move that stabilises the shareholder structure and supports compliance with UK disclosure and takeover thresholds.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 355,000 of its ordinary shares at a volume-weighted average price of 25.62 pence, with all shares to be held in treasury, reducing the number of shares in issue carrying voting rights to 434,793,112. As part of the buyback, the company acquired 105,000 shares from funds managed by Harwood, structured to keep non-executive director Christopher Mills’ aggregate indirect interest at around 30% of EKF’s voting rights, a move that fine-tunes the company’s capital structure while managing significant shareholder influence and regulatory thresholds for disclosure.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 93,980 of its ordinary shares at 25.5 pence each, holding the stock in treasury and reducing the number of shares in issue that carry voting rights to 435,148,112. The buyback included the purchase of 28,000 shares from funds managed by Harwood, structured to keep non-executive director Christopher Mills’ aggregate indirect stake at roughly the same level and below 30% of voting rights, a move that helps manage shareholder concentration while signalling continued capital management activity by the diagnostics group.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the repurchase of 141,000 of its ordinary shares at an average price of 23.5 pence per share, which will be held in treasury. This buyback is part of a strategic move to manage the company’s share capital and maintain stakeholder interests, ensuring that Mr. Mills’ indirect beneficial interest remains stable and does not exceed 30% of the total voting rights. The transaction reflects EKF’s commitment to optimizing its capital structure and could potentially enhance shareholder value.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced the cancellation of 13,710,698 ordinary shares as part of its share buyback program, effective from December 2, 2025. This cancellation reduces the company’s total issued share capital to 435,383,092 ordinary shares, each with one voting right, which will impact shareholders’ calculations under the FCA’s Disclosure and Transparency Rules.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the buyback of 4,395,062 of its ordinary shares at a price of 25 pence per share, which will be held in treasury. This move is part of a strategic effort to manage the company’s share capital and maintain the indirect beneficial interest of Mr. Mills, a significant stakeholder, at a stable level. The buyback is expected to impact the company’s voting rights, with the total number of shares carrying voting rights now at 435,383,092. This transaction reflects EKF’s ongoing commitment to optimizing shareholder value and maintaining a balanced shareholding structure.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the purchase of 141,000 of its ordinary shares at a weighted average price of 25.8 pence per share, which will be held in treasury. This share buyback is part of a strategic move to manage the company’s share capital and maintain the aggregate indirect beneficial interest of Mr. Mills, a non-executive director, at approximately the same level, ensuring it does not exceed 30% of the total voting rights. The transaction reflects EKF’s ongoing efforts to optimize its capital structure and maintain shareholder value.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced an extension to its share buyback program, intending to purchase additional ordinary shares worth approximately £1.0 million. This move follows previous buyback extensions and aims to hold the shares in treasury. The company recently acquired 1,844,000 ordinary shares at a weighted average price of 25.8 pence per share. This buyback is part of a strategy to manage the company’s share capital and maintain shareholder value, with implications for the company’s market positioning and stakeholder interests, particularly in maintaining the indirect beneficial interest of Mr. Mills, a significant shareholder.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced that its total issued share capital consists of 449,093,790 ordinary shares, with 7,330,636 shares held in treasury, resulting in 441,763,154 shares carrying voting rights. This information is crucial for shareholders to determine their interest in the company’s share capital under the Financial Conduct Authority’s Disclosure and Transparency Rules.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has executed a share buyback, acquiring 309,384 ordinary shares at a weighted average price of 26.6 pence per share, which will be held in treasury. This move is part of a strategic decision to manage its share capital and maintain the aggregate indirect beneficial interest of a key stakeholder, Mr. Mills, at approximately the same level, ensuring it does not exceed 30% of the total voting rights. The transaction reflects EKF’s ongoing efforts to optimize shareholder value and manage its equity structure effectively, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced a share buyback, purchasing 283,000 ordinary shares at an average price of 26 pence per share, which will be held in treasury. This transaction, including the acquisition of shares from Harwood as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensures that Mr. Mills’ indirect beneficial interest remains stable and does not exceed 30% of the company’s total voting rights. This strategic move is part of EKF’s efforts to manage its share capital and maintain shareholder value.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced a share buyback, purchasing 1,063,000 of its ordinary shares at a weighted average price of 26 pence per share, which will be held in treasury. This transaction, part of a strategic move to manage the company’s share capital, involves acquiring shares from Harwood as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring Mr. Mills’ beneficial interest remains stable. The buyback reflects EKF’s efforts to optimize its capital structure and maintain shareholder value, potentially impacting its market position and stakeholder interests.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced the repurchase of 410,344 of its ordinary shares at a weighted average price of 25.8926 pence per share, which will be held in treasury. This buyback is part of a strategy to manage the company’s share capital and maintain the indirect beneficial interest of key stakeholders, such as Mr. Mills, who retains an aggregate indirect interest of 130,756,000 shares. The transaction reflects EKF’s ongoing efforts to optimize its capital structure and maintain shareholder value.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced the repurchase of 414,793 of its ordinary shares, which will be held in treasury. This buyback is part of a strategy to maintain shareholder value and manage the company’s capital structure. The transaction involved acquiring shares from Harwood, the investment manager for Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring that Mr. Mills’ indirect beneficial interest remains stable. The buyback reflects EKF’s commitment to optimizing its financial operations and maintaining a balanced approach to its shareholding structure.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced the repurchase of 429,593 ordinary shares at an average price of 26 pence per share, which will be held in treasury. This move is part of a strategic buyback plan to manage share capital and maintain shareholder value, with implications for voting rights and shareholding structures, particularly concerning the interests of Mr. Mills, a significant stakeholder.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced a share buyback, purchasing 400,156 of its ordinary shares at a price of 28 pence each, which will be held in treasury. This transaction, part of a strategic move to manage share capital, involves the acquisition of shares from Harwood, the investment manager for Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring Mr. Mills’ indirect beneficial interest remains stable. The buyback reflects EKF’s commitment to optimizing its capital structure and potentially enhancing shareholder value.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced the purchase of 445,321 of its ordinary shares at a weighted average price of 28 pence per share, which will be held in treasury. This buyback includes a transaction involving the acquisition of shares from Harwood, the investment manager for Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, to maintain Mr. Mills’ indirect beneficial interest in the company. The share buyback impacts the company’s total voting rights, with 445,073,424 shares now carrying voting rights, and reflects strategic financial management to optimize shareholder value.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the purchase of 919,331 of its ordinary shares at an average price of 28 pence per share, which will be held in treasury. The company also extended its share buyback program to include additional purchases of up to £1.0 million. This move is part of a strategy to manage the company’s capital structure and potentially enhance shareholder value. The buyback includes shares acquired from Harwood as an investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring that Mr. Mills’ indirect beneficial interest remains stable. Following the buyback, the total number of ordinary shares carrying voting rights is 445,518,745.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced a share buyback, purchasing 929,169 ordinary shares at a weighted average price of 27.5269 pence per share, which will be held in treasury. This transaction includes a notable acquisition of shares from Harwood, acting as an investment manager for Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring that Mr. Mills’ aggregate indirect interest remains stable. The buyback impacts the company’s total voting rights, now consisting of 446,438,076 shares, and reflects a strategic move to manage shareholder interests and market positioning.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the buyback of 929,169 of its ordinary shares, which will be held in treasury. This move is part of a strategic effort to manage its share capital and maintain the indirect beneficial interest of Mr. Mills, a non-executive director, at a stable level. The transaction involved acquiring shares from Harwood, acting as an investment manager for Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC. The buyback reflects EKF’s ongoing commitment to optimizing shareholder value and maintaining a balanced shareholding structure.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced a share buyback, purchasing 1,017,352 ordinary shares at a weighted average price of 28 pence per share, which will be held in treasury. This move is part of a strategic effort to manage the company’s share capital and maintain the aggregate indirect beneficial interest of Mr. Mills, a non-executive director, at approximately the same level, ensuring it does not exceed 30% of the total voting rights in the company. The transaction involved acquiring shares from Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, facilitated by Harwood, the investment manager.
The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.35 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the repurchase of 709,193 of its ordinary shares at a price of 28 pence per share, which will be held in treasury. This buyback is part of a strategic move to manage the company’s share capital and maintain shareholder value. The transaction includes the acquisition of shares from Harwood as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring that Mr. Mills’ indirect beneficial interest remains stable and does not exceed 30% of the total voting rights. This move could impact the company’s market positioning by potentially increasing shareholder confidence and stabilizing the share price.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £32.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.